Researchers from the California-based nonprit Multidisciplinary Association for Psychedelic Studies (MAPS) presented exciting findings last week at the Psychedelic Science 2017 conference in Oakland.
According to clinical trials conducted by MAPS that involved treating 107 PTSD patients with a combination MDMA and guidance from a mental health pressional, results have shown promising pro that MDMA-assisted psychotherapy could have a significant effect on reducing conditions PTSD like anxiety.
After checking back a year later with patients who had undergone two or three sessions MDMA treatments, 67 per cent reported no longer having symptoms PTSD while only 23 per cent the placebo group reported the same results.
The results are very exciting for MAPS and potentially for the larger community PTSD patients. Last year, the US Food and Drug Administration (FDA) reviewed results the phase II trials and have encouraged the organization to move ahead with the third phase trials.
MAPS aims to bring in a wider pool patients – up to 300 – for phase III. MAPS is also the organization that received a generous earlier this month.